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Influenza vaccines: the effect of 
vaccine dose on antibody 
response in primed 
populations during the 
ongoing interpandemic period. 
A review of the literature 
• . +~ A.M. Palache*, W.E.P. Beyer*, G. Liichters t, R. Voiker , M.J .W. Sprenger *~ 
and N. Masurel* 
Health authorities tend to favour an increase of the antigen 
dose in inactivated influenza vaccines from <~ 10 l~g 
haemagglutinin (HA) per vaccine strain to 151~g 
HA [strain. The increased dose is expected to yield a 
meaningful increase in the number of subjects to be 
protected after vaccination. To verify this expectation, we 
have reviewed 20 published reports (1978-1991) of 
serological studies in which anti-HA-lgG antibody after 
different doses was measured. In the review, stratification 
groups of previously primed subjects were formed and the 
antibody response was estimated for doses of lO and 15 Ilg 
HA by linear k*2-g 2 model Despite a considerable 
beterogenicity ofstudy populations, tudy designs, vaccine 
types and strains, and antibody assays, the results were 
consistent in revealing high protection rates ( >~ 75%) for 
a 10 Itg HA dose of influenza A vaccine components. For 
both response and protection rates, an increase of the 
antigenic load from 10 to 15 pg HA was not associated 
with a meaningful increase of seroresponse: in 38 out of 
39 stratification groups, the increase of response 
and[or protection rate varied between - 9% and + 8%, 
with a median of 1.5%. These results do not justify the 
expectation that a vaccine dose of 15 I~g HA per strain 
would be clinically superior to a dose of 10 l~g HA. Only 
in a group of immune-compromised patients on chronic 
intermittent haemodialysis were results in favour of a 
higher dose found, which may justify further evaluation in 
this special population. 
Keywords: Influenza virus; vaccine; dose; seroresponse 
Infections of influenza A and B viruses cause significant 
mortality in the elderly and in subjects with chronic 
*Department of Virology and WHO Influenza Centre of 
The Netherlands, Erasmus University Rotterdam, PO Box 
1738, 3000 DR Rotterdam, The Netherlands. t Department 
of Haematology, University of Bonn, Bonn, Germany. 
~German Research Centre, Bonn, Germany. ~-To whom 
correspondence should be addressed 
026z#410X/93/09/0892 17 
,(i 1993 Butterworth-Heinemann Ltd 
892 Vaccine, Vol. 11, Issue 9, 1993 
diseases and disabilities. Since their introduction in the 
1940s, inactivated vaccines based on virus material grown 
in fertile hens' eggs have clearly been proven to be 
effective in decreasing mortality in these populations at 
risk whenever there is a sufficient match between the 
vaccine strain and the epidemic wild virus 1'2. The World 
Health Organization maintains aworld-wide surveillance 
on influenza epidemiology and annually reviews the 
strain composition of the vaccine 3. Nowadays, highly 
purified vaccines without serious ide-effects are available. 
Therefore, in many parts of the world, national and 
international health authorities recommend annual 
vaccine administration i subjects at risk for influenza- 
associated complications. Despite the availability of 
influenza vaccines for half a century, uncertainty has 
existed for a long time about the standard vaccine dose. 
In the course of harmonization, doses have been 
standardized internationally. In the United States of 
America, vaccines containing 7.5/~g HA of each of the 
components until 1980; since then, the standard ose has 
been doubled to 15/~g HA. In most European countries, 
10/,g HA has been used until 1991. From 1992 onwards, 
European influenza vaccines will also contain 15/*g HA 
per strain, according to the new European 'Harmonization 
of Requirements For Influenza Vaccines '4. Australian 
influenza vaccines also currently contain 15/~g HA per 
strain. 
Apparently, the preference of health authorities for 
increased vaccine dosages is based on the established 
graded positive relationship between the vaccine dose 
and the resulting IgG antibody response in previously 
primed subjects s 7. Because high serum titres of IgG 
antibody against viral HA protect against infection with 
a homologous virus 8-11, the serological response of this 
antibody upon immunization has become the most useful 
surrogate marker of vaccine fficicy (regardless of the fact 
that, to various degrees, additional immunological 
factors, such as local antibody and cellular immunity, 
contribute to protection). 
The arguments underlying the preference for the higher 
vaccine doses do not, however, address three important 
issues: first, the dose choice of pharmaceutical products 
should, in principle, be based on the concept of 'the lowest 
effective dose' and the benefit-risk ratio of the 
compound; second, vaccine production using fertilized 
hens' eggs is very laborious, involving a variety of 
logistical and environmental problems (risky dependency 
on a biological product, short time interval between the 
availability of annual vaccine strains and the beginning 
of the vaccination season); third, to counter the present, 
generally low, vaccination rates in high-risk patients, 
public campaigns are expected to increase the awareness 
of influenza nd its prevention during the coming years. 
The expected increase in vaccine demand will put an 
enormous pressure on the current production capacity. 
The dependence on hens' eggs for vaccine production 
may then become a limiting factor. 
In the light of these considerations, a standard ose 
of 15/~g HA or higher is justified only if an increase of 
vaccine dose from 10 to 15/~g HA has been shown, by 
scientific means, to be associated with a meaningful 
increase in the number of protected subjects. In this case, 
the three practical elements would be of lesser order. 
From our own work 12 14, we doubted that an increase 
in vaccine dose from 10 to 15/~g HA would have an 
influence on the protection rate to such an extent hat 
a decrease of available vaccine dosages is warranted. 
However, these vaccination trials may have suffered from 
a great variety of factors, such as prior experience of the 
study subjects with other influenza strains, state of health, 
or genetic onditions which may have superimposed a 
dose-effect in a single, limited study 15-17. We therefore 
felt it necessary to review all available recent 
dose-response trials in the international scientific 
literature. We took into consideration the ongoing 
epidemiological situation where both influenza A (H3N2) 
and A (H1Nt) subtypes have been circulating for many 
years (since 1968 and 1978, respectively) and vaccination 
is usually offered to subjects already primed for these 
subtypes. 
MATERIALS AND METHODS 
Source of literature and selection of papers 
The databases Biosis Previes (Philadelphia, PA, USA), 
Medline (National Library of Medicine, Bethesda, ML, 
USA), and Embase (Excerpta Medica, Amsterdam, The 
Netherlands) were searched for various combinations 
of the keywords 'influenza', 'vaccine' (vaccination), 
'immunisation' (immunization) and 'dose' (doses, dosing, 
dosage, dosages) in papers written in English. The search 
was undertaken i January 1992 and covered the period 
January 1978 through December 1991. 
Serological studies using the single-radial immuno- 
diffusion (SRD) method to determine the antigen dose 
were selected for this review. The year 1978 was chosen 
for the following reason: since 1967, the antigenic 
contents of vaccines had been estimated by comparison 
with an international influenza A standard preparation 
and expressed in chick red blood cell agglutination (CCA) 
units. This method was not always reliable as it tended 
to underestimate vaccine contents when whole-virus 
particles were aggregated. Moreover, with the develop- 
ment of split and subunit vaccines, this technique 
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became impractical, because it produced extremely high 
values. Free haemagglutinin molecules can agglutinate 
erythrocytes more effectively than virus-bound haemag- 
glutinin 18. In 1978, the World Health Organization 
replaced the CCA method by the SRD test which 
expresses antigenic vaccine contents as pg HA 19. 
Dose-response tudies thus became more reliable 2°. 
Studies were selected in which at least wo doses of an 
inactivated, aqueous influenza vaccine (whole-virus, WV; 
split, SPL; subunit, SU) without adjuvant were 
administered, in a randomized fashion, by the intra- 
muscular or subcutaneous route. Any study design was 
accepted which included the sampling of two blood 
specimens (one before and a second after immunization), 
and the detection of IgG antibody against viral 
haemagglutinin by an appropriate assay. Tests measuring 
antibodies directed against other viral proteins (neur- 
aminidase, M-protein) or measuring cellular immunity 
were excluded, in view of their unknown quantitative 
association with protection. Some studies include booster 
doses several weeks after the first immunization. In this 
review, data were selected from either the first or the 
second vaccination i  view of the following: in subjects 
already primed for a given subtype, a booster vaccination 
will generally not increase antibody titres after the first 
vaccination with an influenza strain belonging to that 
same subtype. On the other hand, subjects not previously 
exposed to a given subtype (i.e. very young children, and 
defined age groups after first occurrence of pandemic 
strains), respond insufficiently to a first immunization 
and need a booster dose to reach an antibody level 
comparable toprimed subjects. Obviously, in previously 
unprimed subjects, the first dose serves as primer which 
enables an adequate antibody production after booster 
dose 21-25. As we were interested in dose-response 
statements in primed populations, we selected ata on 
first vaccination in primed subjects, and on booster 
vaccination i  previously unprimed subjects. 
Measures of serological response, and statistical analysis 
In the selected publications which used the 
haemagglutination nhibition (HI) test or the indirect 
immunofluorescence (IIF) test, seroresponse was expressed 
by using one or more of the following measures: (1) the 
pre- and postvaccination geometric mean titres (GMT) 
and/or the difference between the logarithms of post- and 
pre-GMT (mean fold increase, MFI), (2) the protection 
rate (PR), i.e. the proportion of subjects exceeding a given 
protection threshold after vaccination, (3) the response 
rate (RR), i.e. the proportion of subjects howing at least 
a fourfold titre increase after vaccination. The data were 
taken directly from the selected papers, recalculated from 
their original data if given, or derived from appropriate 
original tables or figures. For calculation of the 
protection rate, a titre threshold of 408'16'24 was used, 
if not mentioned otherwise by the authors. 
One paper in which a single radial haemolysis test is 
described 25 presented pre- and postvaccination a tibody 
concentrations as haemolysis areas (in mm2), which were 
treated as GMT values in our analysis except for the 
logarithmation step. Post-GMT or MFI values could not 
be statistically analysed any further by us given the lack 
of original individual data. The significance level of 
differences between dose groups was taken from the 
original paper is given. 
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An example of the method used to estimate protection and Figure 1 
response rates for doses of 10 and 15 #g HA from observed rates, per 
stratification group, by the linear k*2-~ model. I-1, Observed values for 
doses other than 10 and 15/~g HA; c~, I, straight line, calculated from 
observed values, with slope tan :( and y-intercept/; +,  estimated values 
for 10 and 15/~g HA 
PR and RR values were subjected to probit analysis z6 
(PROBIT in SAS 6.06) as it is the procedure often 
practised in literature. However, this method has 
preconditions which may not be met by all studies. In 
order to use a uniformly well-fitting method for all 
studies, we also applied the linear k*2-Z 2 model 27 which 
has fewer preconditions on the data than probit analysis. 
With either method, protection and response rates were 
estimated for the 10 and 15/~g HA doses, as exemplified 
in Figure 1. 
The protection rate was supposed to be the most 
meaningful response measure. We assumed that an 
influenza vaccine should produce protection in at least 
75% of primed but unprotected subjects, during the 
interpandemic period. 
RESULTS 
Papers reviewed (Table 1) 
The literature search for the period 1978 through 1991 
produced 180 English-language papers. From these, the 
titles of 84 papers revealed that they dealt with subjects 
other than trials with inactivated influenza vaccines in 
humans, for example trials with experimental live 
vaccines, or trials in animals. The remaining 96 papers 
were read for the presence of dose-comparison data in 
primed populations, which were found in 32 papers. Of 
these, 12 papers were not included: two 2°'28 were, 
respectively, a summary and a part of a national trial 
which is described in three included papers29-31; one 
study (Ref. 32) described the same trial as Ref. 33 using 
a different serological technique; another 34 covers a 
selection of the study population which is described in 
the included paper35; one study 36 does not describe a 
previously planned trial with at-random allocation, but 
an accident during a mass vaccination campaign, and 
seven papers 37-43 used the obsolete CCA test to 
determine the vaccine dose. 
Table 1 presents the first authors and the years of 
publication of the selected papers, as well as the years 
and places of performance. Eleven studies were 
conducted in Northern America, and nine in Europe. 
The first six trials were performed in 1978 using the 
A/USSR/77 (H1N1) virus. The virus had been detected 
in November 1977 in the Soviet Union and was 
antigenically closely related to influenza A-H1N1 strains 
which had circulated 30 years earlier 5~'58. 
Characteristics of study populations (Table 1) 
Size and health state. The size of the study 
populations varied widely between 30 s6 and 2062 
subjects 54. A total of 7328 subjects entered the 20 selected 
studies but, in many papers, not all these subjects could 
be included in this review for various reasons (for 
example, insufficient data, interference with natural 
influenza during vaccination campaign, or subgroups 
which were not offered different vaccine doses). The 
reasons for exclusion are described in detail in 
Appendix 1. 
Four papers 12,2s'33'4s included exclusively young 
adults. Children and adolescents (~< 15 years of age) were 
included in four papers 31,35,46.54, and elderly (~> 65 years 
of age) in nine papers z9'3°'35'44'45,5° 2.55. Most papers 
dealt with 'apparently healthy' volunteers, typically 
pupils, university students and employees. None of these 
papers established the absence of illness in these subjects 
by clinical or laboratory measures. One study 29 included 
both healthy and chronically ill subjects, and five studies 
were conducted in chronically ill patients at risk for 
influenza complications, such as sufferers from cystic 
fybrosis 46, renal diseases demanding haemodialysis 55, 
and various chronic geriatric diseases 45'5°'52. Of these 
chronically ill populations, only patients on haemodialysis 
have been established as suffering from a compromised 
humoral immunity and to show an impaired seroresponse 
to vaccines 59-62. 
Previous exposure to influenza. Of the 20 papers, 
eight 25'29'35'48'49'51'55'56 did not take into account he 
influence of homologous prevaccination antibody titres 
on the seroresponse. In the other studies, this issue was 
addressed, although in different ways. Two papers 
described a prescreening of subjects for low pre-existing 
antibody titres before intake 12'a3. Five papers retro- 
spectively stratified for prevaccination antibody 3°'44 47, 
two papers excluded all previously seropositive 
subjects a1'54, and two excluded retrospectively all 
subjects with high (protective) prevaccination titres ~ 2.5o. 
Two studies 52"53 included prevaccination titres in a 
statistical model and adjusted for this factor by regression 
analysis or analysis of covariance. 
Seven papers 12'29'3°'45'47'51'52 gave information about 
the history of previous vaccination against influenza, but 
drew different consequences from that information; study 
designs varied considerably from exclusion of all 
previously vaccinated subjects 12 to inclusion of up to 
74% 52 or  82% 29 of previously vaccinated subjects in the 
study samples. 
All six studies performed in 1978 to test the new 
influenza A/USSR/77 (H1N1) strain addressed correctly 
the H1Nl-priming period by stratifying for age. Of the 
14 remaining, more recent studies, five 12'33"46'47'54 
addressed priming periods by a restricted prospective age 
selection of the participants, or by stratification for age. 
Characteristics of study designs (Table 1, Appendix 1) 
Randomization. An essential requirement of a dose- 
comparative study to validate its statistical analysis 
894 Vaccine, Vol. 11, Issue 9, 1993 
T
a
b
le
 
1
 
C
h
a
ra
c
te
ri
s
ti
c
s
 o
f 
th
e
 2
0
 p
u
b
li
c
a
ti
o
n
s
 s
e
le
c
te
d
 fo
r 
re
v
ie
w
 
S
tu
d
y
 p
o
p
u
la
ti
o
n
s 
S
tu
d
y
 d
e
si
g
n
 
S
e
ro
lo
g
ic
a
l m
e
a
s
u
re
s
 
Y
e
a
r 
a
n
d
 
S
e
ro
- 
P
ro
te
c
ti
o
n
 
R
e
f.
 
F
ir
st
 
Y
e
a
r 
o
f 
p
la
c
e
 o
f 
In
it
ia
l 
A
g
e
 
P
re
- 
V
a
c
c
. 
R
a
n
d
o
m
i-
 
lo
g
ic
a
l 
P
re
- 
P
o
st
- 
ra
te
 
R
e
sp
o
n
se
 
n
o
. 
a
u
th
o
r 
p
u
b
li
c
a
ti
o
n
 
st
u
d
y
 
si
ze
 
ra
n
g
e
 
H
e
a
lt
h
 s
ta
te
 
v
a
c
c
. 
h
is
t.
 
P
ri
m
in
g
 
za
ti
o
n
 
B
li
n
d
n
e
ss
 
B
o
o
s
te
r 
P
la
c
e
b
o
 
te
st
 
G
M
T
 
G
M
T
 
th
re
sh
o
ld
 
ra
te
 
S
ta
ti
st
ic
s 
3
5
 
N
ic
h
o
ls
o
n
 
1
9
7
9
 
1
9
7
8
 
G
B
 
1
3
3
5
 
1
2
 8
5
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
d
b
 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
4
4
 
L
a
v
e
rg
n
e
 
1
9
8
0
 
1
9
7
8
 
C
A
N
 
6
6
7
 
1
8
 7
3
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
Y
e
s 
d
b
 
H
I 
Y
e
s 
Y
e
s 
c
o
n
y
 
4
5
 
B
ra
n
d
ri
ss
 
1
9
8
1
 
1
9
7
8
 
U
S
A
 
1
3
7
 
4
1
 
9
3
 
C
h
r.
il
l,
 n
-i
n
st
. 
Y
e
s 
Y
e
s 
Y
e
s 
Y
e
s 
d
b
 
Y
e
s 
Y
e
s 
H
I 
- 
Y
e
s 
- 
c
o
n
v
 
2
9
 
Q
u
in
n
a
n
 
1
9
8
3
 
1
9
7
8
 
U
S
A
 
5
1
7
 
1
6
 8
3
 
Y
e
s 
Y
e
s 
d
b
 
Y
e
s 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
Y
e
s 
c
o
n
v
 
3
0
 
C
a
te
 
1
9
8
3
 
1
9
7
8
 
U
S
A
 
2
9
2
 
2
0
 8
8
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
Y
e
s 
Y
e
s 
Y
e
s 
H
I 
- 
Y
e
s 
(4
0
) 
c
o
n
y
 
3
1
 
W
ri
g
h
t 
1
9
8
3
 
1
9
7
8
 
U
S
A
 
1
0
3
4
 
3
 
2
5
 
H
e
a
lt
h
y
-c
h
r.
il
l 
Y
e
s 
Y
e
s 
N
o
? 
- 
Y
e
s 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
c
o
n
y
 
4
6
 
C
ro
ss
 
1
9
8
2
 
1
9
8
0
 
U
S
A
 
8
0
 
3
 
3
3
 
C
h
r.
il
l,
 in
st
. 
Y
e
s 
- 
Y
e
s 
Y
e
s 
d
b
 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
Y
e
s 
c
o
n
y
 
4
7
 
M
o
ff
a
t 
1
9
8
2
 
1
9
8
0
 
G
B
 
1
0
8
 
1
7
 6
3
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
Y
e
s 
Y
e
s 
d
b
 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
Y
e
s 
c
o
n
y
 
3
3
 
G
o
o
d
e
v
e
 
1
9
8
3
 
G
B
 
1
1
9
 
1
8
-1
9
 
H
e
a
lt
h
y
 
Y
e
s 
- 
Y
e
s 
Y
e
s 
d
b
 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
Y
e
s 
4
8
 
R
u
d
e
n
k
o
 
1
9
8
5
 
U
S
S
R
 
8
0
 
1
8
 2
5
 
H
e
a
lt
h
y
 
Y
e
s 
- 
Y
e
s 
Y
e
s 
H
I 
Y
e
s 
Y
e
s 
- 
Y
e
s 
- 
2
5
 
Je
n
n
in
g
s 
1
9
8
5
 
1
9
8
3
 
G
B
 
1
3
2
 
Y
A
 
H
e
a
lt
h
y
 
Y
e
s 
d
b
 
Y
e
s 
S
R
H
 
Y
e
s a
 
Y
e
s a
 
Y
e
s ~
 
c
o
n
y
 
4
9
 
C
la
rk
e
 
1
9
8
5
 
G
B
 
1
0
0
 
1
8
 6
1
 
H
e
a
lt
h
y
 
Y
e
s 
- 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
- 
5
0
 
A
rd
e
n
 
1
9
8
6
 
1
9
8
4
 
U
S
A
 
5
0
 
5
8
-9
9
 
C
h
r.
il
l,
 in
st
. 
Y
e
s 
Y
e
s 
- 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(4
0
) 
c
o
n
y
 
5
1
 
G
ro
ss
 
1
9
8
8
 
1
9
8
4
 
U
S
A
 
1
6
9
 
E
ld
e
rl
y
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
sb
 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
c
o
n
y
 
1
2
 
B
e
y
e
r 
1
9
8
6
 
1
9
8
5
 
N
L 
9
4
 
2
0
 3
5
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
Y
e
s 
Y
e
s 
sb
 
- 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(1
0
0
) 
Y
e
s 
c
o
n
y
 
5
2
 
P
e
te
rs
 
1
9
8
8
 
1
9
8
5
 
U
S
A
 
1
3
1
 
7
0
 9
6
 
C
h
r.
il
l,
 n
-i
n
st
. 
Y
e
s 
Y
e
s 
Y
e
s 
d
b
 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
(3
2
) 
Y
e
s 
a
d
v
 
5
3
 
S
u
ll
iv
a
n
 
1
9
9
0
 
1
9
8
5
 
U
S
A
 
1
4
0
 
1
8
 6
4
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
d
b
 
H
I 
Y
e
s 
Y
e
s 
a
d
v
 
5
4
 
S
u
b
b
o
ti
n
a
 
1
9
8
8
 
U
S
S
R
 
2
0
6
2
 
9
 
2
2
 
H
e
a
lt
h
y
 
Y
e
s 
Y
e
s 
N
o
? 
- 
H
I 
Y
e
s 
Y
e
s 
Y
e
s 
c
o
n
y
 
5
5
 
R
a
u
te
n
b
e
rg
 
1
9
8
9
 
1
9
8
7
 
FR
G
 
5
1
 
2
2
 7
7
 
H
a
e
m
o
d
ia
ly
s
is
 
Y
e
s 
II
F
 
Y
e
s 
Y
e
s 
Y
e
s 
(2
5
5
5
) 
Y
e
s 
c
o
n
v
 
5
6
 
G
u
a
rn
a
c
c
ia
 
1
9
9
0
 
U
S
A
 
3
0
 
2
0
 5
0
 
H
e
a
lt
h
y
 
- 
H
I 
Y
e
s 
Y
e
s 
a
d
v
 
<
 
<
 
O
 
(/
) 
r-
 ~o
 
(D
 
EO
 
G
O
 
(D
 
O
1 
Y
A
, 
y
o
u
n
g
 a
d
u
lt
s;
 c
h
r.
ill
, 
c
h
ro
n
ic
a
ll
y
 ill
; 
in
st
.,
 i
n
st
it
u
ti
o
n
a
liz
e
d
; n
-i
n
st
.,
 n
o
n
-i
n
st
it
u
ti
o
n
a
liz
e
d
; P
re
-v
a
cc
. 
p
re
v
a
cc
in
a
ti
o
n
 s
ta
te
 (
a
m
o
u
n
t o
f 
h
o
m
o
lo
g
o
u
s a
n
ti
b
o
d
y
 b
e
fo
re
 v
a
cc
in
a
ti
o
n
) 
a
d
d
re
ss
e
d
; 
V
a
cc
.h
is
t.
, 
h
is
to
ry
 o
f 
p
re
v
io
u
s 
v
a
c
c
in
a
ti
o
n
s 
a
d
d
re
ss
e
d
; 
P
ri
m
in
g
, 
p
ri
m
in
g
 p
e
ri
o
d
s 
a
d
d
re
ss
e
d
; 
R
a
n
d
o
m
iz
a
ti
o
n
: 
n
o
?,
 
ra
n
d
o
m
iz
a
ti
o
n
 d
o
u
b
tf
u
l 
(s
e
e
 
A
p
p
en
d
ix
 1
);
 
d
b
, 
d
o
u
b
le
-b
lin
d
; 
sb
, 
si
n
g
le
-b
lin
d
; 
H
I,
 
h
a
e
m
a
g
g
lu
ti
n
a
ti
o
n
 in
h
ib
it
io
n
; 
S
R
H
, 
si
n
g
le
 r
a
d
ia
l 
h
a
e
m
o
ly
si
s;
 I
IF
, 
in
d
ir
e
c
t 
im
m
u
n
o
fi
u
o
re
sc
e
n
ce
; co
n
y
, c
o
n
v
e
n
ti
o
n
a
l;
 a
d
v
, a
d
v
a
n
ce
d
; n
o
t g
iv
e
n
 o
r 
n
o
t a
d
d
re
ss
e
d
 
a
H
a
e
m
o
ly
si
s a
re
a
 in
 m
m
 2
 
b
B
a
se
d
 o
n
 s
u
b
je
ct
s w
it
h
 a
n
 i
n
cr
e
a
se
 o
f 
h
a
e
m
o
ly
si
s a
re
a
 >
4
5
%
 
~3
 
(3
 o~
 
co
 
G
) 
Influenza vaccine dose: A.M. Palache et al. 
is the random allocation, per stratification group, of 
the different doses to subjects. Fourteen papers 
addressed random allocation explicitly, but six other 
papers 29-31'54-56 did not report on this point. 
Considering the context and background of the 
institution, one may assume, however, that randomization 
had been performed, except possibly for two papers 31,54 
Blinding and placebo control. Double- or single- 
blinding and placebo control are essential when scoring 
for local and systemic adverse effects of the vaccines. 
When the objective ndpoint is the induction of antibody, 
blinding is less critical. However, a placebo group is 
advisable when vaccine trials are done during a period 
when an outbreak of natural influenza may occur. Indeed, 
two studies z5~35 reported such an event. Seven 
studies zS'29-31'33'45'4s included a placebo. 
Techniques and calculations (Table l) 
Serological tests. In all but two papers 25'55, the HI 
test was used to detect homologous antibodies against 
the viral vaccine components, performed in a microtitre 
fashion. This test has many variations (for instance, 
pretreatment of sera, incubation periods, type of 
erythrocytes, treatment of test antigen, recording of 
agglutination patterns). Moreover, the concentration of 
the test antigen (measured in haemagglutination u its, 
HAU) affects the outcome of the test: a low concentration 
(3 HAU, Ref. 12) increases absolute titre values and may 
detect even small amounts of antibody with a higher 
chance of false-positive results (high sensitivity, low 
specificity); a high concentration (8 HAU, Refs 33, 35) 
results in a lower sensitivity and lower absolute titre 
values, but in better reproducibility. Most studies did 
not mention the amount of HAU used but referred to 
previous publications which were also consulted in this 
review. From this, it can be concluded that, in most cases, 
4 HAU had been used in the HI tests. 
Measures of serological response. Table 1 presents 
also the measures of serological response which we could 
review. The pre- and postvaccination geometric mean 
titres (GMT), or measures derived from them, were the 
most common parameters to describe quantitatively the 
antibody response to the vaccine. Many papers also 
reported numbers, percentages or proportions of subjects 
under and beyond a threshold titre believed to correlate 
with protection. The threshold was a titre of 32-40 for 
those studies which used a test-antigen concentration of 
4-8  HAU in the HI test, and higher (100 and 200, for 
influenza A and B, respectively) in the study which used 
3 HAU 12. The indirect immunofluorescence assay used 
in Ref. 55 had a threshold of 2555. Numbers, percentages 
or rates expressing 'response' (titre rise of at least 
fourfold) were also often given. The paper in which the 
single radial haemolysis test was used 25, also presented 
response rates (based on the number of subjects within 
an increase of more than 45% between pre- and 
postvaccination haemolysis areas). Seven papers presented 
pre- or postimmunization titres in cumulative tables for 
discrete titre intervals 31,33,35,44.49,51,52. 
Statistical analysis. The final column of Table 1 
provides an indication of the statistical methods used to 
assess the significance of differences found between dose 
groups. No formal statistical analysis at all was applied 
in four studies 33'35'4s'49. In these studies, the absolute 
differences between groups were presented without 
addressing factors such as group size and probability 
calculations, i.e. statistical considerations which could 
affect the interpretation of the outcome. Other 
papers 12'25'29-3a'4~47"5°'54'55 usedconventional statistical 
methods uch as )~2, Fisher's exact, t, or Wilcoxon-rank 
tests where thought appropriate. Three of the most recent 
studies 52'53'56 applied more advanced statistical pro- 
cedures such as regression analysis, or analysis of 
variance. None of the published studies presented ata 
indicating the amount of variation within the study 
groups for the observed values, such as ranges of observed 
titre values, or 95% confidence intervals with the reported 
dose differences in means and rates. 
Stratification groups, doses and serological data ( Table 2) 
Many of the 20 papers included more than one vaccine 
type (WV and SU 35, WV and SPL 29 31.45) or more 
than one influenza s t ra in  12'25'29 31,44,45,47 49.51 ,53  56 
Subjects were stratified, by the authors, according to 
various criteria. For this review, the groups for 
dose-comparisons were either adopted as reported in the 
original papers, or restratified as described in detail in 
Appendix 1. Data on different vaccine types were pooled 
by us where they showed no significant difference in 
antibody titres, according to the authors. Data on 
different influenza strains, however, were never pooled. 
Table 2 presents the results of this restratification 
procedure. Fifty stratification groups (SG) were derived 
from the 20 studies. SPL, WV and SU vaccines were used 
in 27, 22 and nine stratification groups, respectively 
(double scoring possible). Two papers 52'56 did not report 
the type of their vaccines. Many of the vaccine strains 
belonged to the influenza A-H1NI subtype (20 SG) with 
the A/USSR/92/77 virus as the most frequent single 
strain (nine SG); the remaining strains consisted of 
influenza B (16 SG) and A-H3N2 (14 SG) viruses. 
The sample size of the stratification groups varied 
widely (between 29 and 1137 subjects). In bi- and trivalent 
vaccine studies, the same subjects are scored two or three 
times, separately for each strain. The total number of 
subjects in Table 2 (8921 subjects) is therefore 
considerably larger than the actual number of included 
subjects (7328 subjects). This assumes that after 
administration of bi- or trivalent vaccines, the antibody 
induction in any one subject is independent for each 
vaccine component. For further calculations, each 
stratification group is assumed to be a single, independent 
dose-response experiment. 
The final column of Table 2 shows the vaccine doses 
tested for each of the 50 stratification groups, varying 
between 1.5 and 94/~g HA. Some stratification groups 
contain only two doses, others up to six. A complete list 
of available serological data for each dose of each 
stratification group, which was used for the collection of 
raw data for this review, is given in Appendix 2. 
Dose comparisons 
Dose comparisons of quantitative parameters (Table 
3). It was not possible for us to apply statistical 
procedures on pre-GMT, post-GMT, or MFI values. 
because no reference was made to within-group 
variances, and the original raw data were not available. 
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Table 2 Characteristics of 50 stratification groups, derived from 20 studies 
Stratification Vaccine Dosages 
Ref. group type Strain Size (/~g HA) 
35 WV 
WV 
SU 
44 WV 
WV 
WV 
WV 
WV 
WV 
WV 
WV 
WV 
WV 
WV. 
WV. 
WV. 
WV 
WV 
46 SPL 
47 WV 86 
WV 103 
33 SU 96 
48 SU 59 
SU 59 
25 SU 95 
SU 95 
49 SPL 96 
SPL 96 
50 SPL 50 
51 SPL 72 
SPL 72 
SPL 72 
WV 75 
WV 75 
WV 75 
12 SPL 84 
SPL 76 
SPL 82 
52 - 129 
53 SU 140 
SU 140 
SU 140 
54 WV 1137 
WV 1137 
55 SPL 51 
SPL 51 
SPL 51 
56 _ 29 
- 29 
- 2 9  
45 
29 
30 
31 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
3O 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
5O 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
SPL 
A/USSR/92/77 (H1N1) 175 5, 9, 16, 32, 47, 94 
A/USSR/92/77 (H1N1) 128 5, 9, 16, 32, 47, 94 
A/USSR/92/77 (H1N1) 61 5, 18, 66 
A/Texas/ I /77 (H3N2) 590 7.5, 15.5 
A/USSR/92/77 (H1N1) 306 6, 10.5 
B/Hong Kong/8/72 590 19.5, 33.5 
A/USSR/92/77 (H1N1) 137 7, 20 
A/Texas/ I /77 (H3N2) 137 7, 20 
A/USSR/92/77 (HIN1) 132 7, 20 
A/USSR/92/77 (H1N1) 185 7, 20, 60 
A/Texas/ I /77 (H3N2) 260 7, 20 
B/Hong Kong/8/72 260 7, 20 
A/USSR/92/77 (H1N1) 57 7, 20 
A/Texas/ I /77 (H3N2) 218 7, 20 
B/Hong Kong/8/72 218 7, 20 
A/USSR/92/77 (H1N1) 355 2.3, 7, 20 
A/Texas/1/77 (H3N2) 111 2.3, 7, 20 
B/Hong Kong/8/72 229 2.3, 7, 20 
B/Singapore/222/79 47 7, 60 
A/Brazil/11/78 (H1N1) 7, 10 
B/Singapore/222/79 7, 15 
B/Hong Kong/?/73 5, 10, 20, 40 
A/Khabarovsk/74/77 (H1N1) 7.5, 15, 20 
A/Texas/ I /77 (H3N2) 7.5, 15, 20 
A/Bangkok/I/79 (H3N2) 6, 12, 24 
A/Brazil/11/78 (H1N1) 6, 12, 24 
A/Chi le/ I /83 (H1N1) 10, 15 
B/USSR/100/83 10, 15 
B/USSR/100/83 15, 60 
A/Philippines/2/82 (H3N2) 15, 30, 45 
A/Chi le/ I /83 (H1N1) 15, 30, 45 
B/USSR/100/83 15, 30, 45 
A/Philippines/2/82 (H3N2) 15, 30, 45 
A/Chi le/ I /83 (H1N1) 15, 30, 45 
B/USSR/100/83 15, 30, 45 
A/Philippines/2/82 (H3N2) 10, 15 
A/Chi le/ I /83 (H1N1) 10, 15 
B/USSR/100/83 10, 15 
B/USSR/100/83 15, 60 
A/Philippines/2/82 (H3N2) 7.5, 15, 30 
A/Chi le/ I /83 (H1N1) 7.5, 15, 30 
B/USSR/100/83 7.5, 15, 30, 45 
A/Kiev/59/79 (H1N1) 7, 14 
A/Leningrad/385/80 (H3N2) 7, 14 
A/Singapore/6/86 (H1N1) 15, 30 
A/Leningrad/360/86 (H3N2) 15, 30 
B/Ann Arbor/I /86 10, 20 
A/Leningrad/360/86 (H3N2) 1.5, 3, 15 
A/Taiwan/1/86 (H1N1) 1.5, 3, 15 
B/Ann Arbor/186 1.5, 3, 15 
WV, whole-virus vaccine, SPL, split vaccine, SU, subunit vaccine 
Thus, the papers were checked for statistical calculations 
computed by the authors themselves. Table 3 presents 
those 39 stratification groups where the result of a 
statistical test on post-GMT or MFI had been reported 
by the authors. In column 'Result' of Table 3, '+ '  
indicates that the authors found a statistically significant 
difference between doses (~<0.05), and ' - '  means its 
absence. This descriptive review procedure revealed 11 
significant stratification groups out of 39 (28%). There 
was no clear association between the result of the 
significance tests and the size of the stratification groups 
or the subtype/type of the vaccine strain (not shown). 
Very small total dose ranges (~<7/~g HA) showed no 
significant dose differences (SG 5, 20, 36-38, 43, 44), but 
the other dose ranges did not correlate with the outcome; 
there were stratification groups with a large dose range 
which could not detect a significant dose-response 
relation (SG 10, 7-60/zg HA, SG 29 and SG 31, 15-60/~g 
HA). 
Dose comparisons of protection rates (Table 4). 
Protection rates as reported in, or derived from, the 
reviewed papers, were subjected to statistical analysis, i.e. 
a weighted linear model based on the k*2-Z 2 test, and 
probit analysis. Table 4 presents, ubdivided for influenza 
subtype/type and immune status, the results of these 
calculations for 26 stratification groups for which 
protection rates were available. For each stratification 
group with more than two doses, both methods were 
tested for model-fitting. For an acceptable fit, the test 
value should be greater than 0.I0, which was not true 
for one stratification group (SG 1). Results from another 
five stratification groups (SG 20, 29, 39, 45, 46) should 
be interpreted cautiously since their doses do not include 
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Table 3 Significance of dose differences in post-geometric mean titres, or mean fold increase values, in studies that performed and reported statistical 
tests 
Dose (#g HA) 
Ref. Stratification Dose range Dose 
no. group Size Minimum Maximum (/zg HA) number 
44 4 590 7.5 15.5 8.0 2 
44 5 306 6.0 10.5 4.5 2 - 
44 6 590 19.5 33.5 14.0 2 + 
45 7 137 7.0 20.0 13.0 2 ÷ 
45 8 137 7.0 20.0 13.0 2 + 
29 9 132 7.0 20.0 13.0 2 
29 10 185 7.0 60.0 53.0 3 
29 11 260 7.0 20.0 13.0 2 - 
29 12 260 7.0 20.0 13.0 2 - 
31" 16 355 2.3 20.0 17.7 3 
31" 17 111 2.3 20.0 17.7 3 
31 ~ 18 229 2.3 20.0 17.7 3 - 
46 19 47 7.0 60.0 53.0 2 + 
47 20 86 7.0 10.0 3.0 2 
47 21 103 7.0 15.0 8.0 2 4- 
25 25 95 6.0 24.0 18.0 3 
25 26 96 6.0 24.0 18.0 3 
50 29 50 15.0 60.0 45.0 2 
51 30 72 15.0 45.0 30.0 3 
51 31 72 15.0 45.0 30.0 3 + 
51 32 72 15.0 45.0 30.0 3 
51 33 75 15.0 45.0 30.0 3 
51 34 75 15.0 45.0 30.0 3 
51 35 75 15.0 45.0 30.0 3 
12 36 84 10.0 15.0 5.0 2 
12 37 76 10.0 15.0 5.0 2 
12 38 82 10.0 15.0 5.0 2 
52 39 129 15.0 60.0 45.0 2 
53 40 140 7.5 30.0 22.5 3 
53 41 140 7.5 30.0 22.5 3 + 
53 42 140 7.5 45.0 37.5 4 
54" 43 1137 7.0 14.0 7.0 2 
54" 44 1137 7.0 14.0 7.0 2 
55 45 51 15.0 30.0 15.0 2 4- 
55 46 51 15.0 30.0 15.0 2 + 
55 47 51 10.0 20.0 10.0 2 
56 48 29 1.5 15.0 13.5 3 + 
56 49 29 1.5 15.0 13.5 3 + 
56 50 29 1.5 15.0 13.5 3 
Result ~ 
Note that, for some stratification groups, the sizes may differ in Appendix 2 and in Tables 3 5, due to 
original papers and those by us (see Appendix 1) 
aPossibly not randomized 
4- / - ,  authors found/did not find a statistically significant difference between dose groups 
differences between inclusion criteria in the 
l0 and 15 #g HA. These doses had to be extrapolated 
with possibly doubtful validity. 
Table 4 also presents intercept and slope of the linear 
model. Interestingly, six out of 26 stratification groups 
(23%) showed a negative slope, and one a slope equal 
to zero. In these studies, higher vaccine doses were 
associated with lower or equal protection rates. Of the 
remaining ! 9 positive slopes, only three were significantly 
different from zero, thus showing a significant dose 
response relationship (SG 16, 19, 22). 
Intercept and slope were used to estimate protection 
rates for l 0 and 15 #g HA doses. Despite the considerable 
differences between studies and the significance levels of 
the model parameters, these results were very consistent 
for influenza A: all four stratification groups with 
A-H3N2 vaccine strains, and nine from ten stratification 
groups with A-H 1N1 strain had protection rates greater 
than 75% at a dose of 10 #g HA. The median PR for all 
14 influenza A strains was 81.5% with a range of 
70 93%. For influenza B (9 SG), protection rates at 
10 #g HA were more heterogeneous and generally lower 
than for the influenza A strains (range 51-97%, median 
68%, six out of nine SG lower than 75%). This may 
reflect differences in laboratory techniques (some 
studies t2'5°'52'53 used ether-treated test antigen in the HI 
test, others did not), or in the definition of a protection 
threshold. 
The estimated PR values at 15 #g HA were not much 
different from those at 10#g HA in non-immune- 
compromised populations. The difference between the 
protection rates varied between -3  and 6% in 22 out 
of 23 stratification groups with a median of 1%. The 
three stratification groups with a significantly positive 
slope did not differ from this pattern. Only SG 20, one 
of the stratification groups which should be interpreted 
cautiously, had a higher difference between the two doses 
(11%) but this may be meaningless, as this is the only 
stratification group with an extremely narrow dose range 
which makes extrapolation very unreliable (in the study, 
doses of 7 and 10 #g HA were compared). Moreover, the 
estimated (and real) PR value at 10 #g HA is already 
very high (91%), and the extrapolated PR value at 15 #g 
HA would exceed 100%. For the immune-compromised 
population represented in this review, patients on 
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Table 4 Estimation of protection rates for doses of 10 and 15/zg HA 
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Linear k*2 Z ~ analysis 
Doses Dose (/zg) 
Ref. Stratification Model 
no. group Subtype Size No. Min. Max. fit Intercept Slope 10 15 Difference 
Probit analysis 
Dose (#g) 
Model 
fit 10 15 
Non-immune-compromised populations 
29 11 H3N2 185 2 8.8 22.5 0.769 0.0012 0.78 0.79 0.01 
30 14 H3N2 141 2 7.0 20.0 0.814 --0.0066 0.75 0 .71  --0.04 
31a 17 H3N2 111 3 2.3 20.0 0.22 0.757 0.0008 0.76 0.77 0.01 
12 36 H3N2 84 2 10.0 15.0 0.785 0 .0126 0.91 0.97 0.06 
35 1 HIN1 172 6 5.0 94.0 0.01 0.777 0.0032 0.81 0.83 0.02 
35 2 H1N1 103 6 5.0 94.0 0.41 0.920 0.0000 0.92 0.92 0.00 
35 3 H1N1 50 3 5.0 66.0 0.44 0.854 0.0024 0.88 0.89 0.01 
29 9 H1N1 68 2 5.8 16.8 0.738 0 .0052 0.79 0.82 0.03 
29 10 H1N1 79 3 5.8 52.0 0.67 0.782 0.0024 0.81 0.82 0.01 
30 13 H1N1 76 2 7.0 20.0 0.728 0.0096 0.82 0.87 0.05 
31 a 16 HIN1 355 3 2.3 20.0 0.50 0.607 0.0092 ~ 0.70 0.75 0.05 
47 20 HIN1 86 2 7.0 10.0 0.703 0 .0210 0.91 1.02 0.11 
49 27 HIN1 59 2 10.0 15.0 0.926 0.0004 0.93 0.93 0.00 
12 37 H1N1 76 2 10.0 15.0 0.937 -0.0056 0.88 0.85 --0.03 
29 12 B 169 2 7.8 24.0 0.594 0 .0012 0.61 0.61 0.00 
30 15 B 149 2 7.0 20.0 0.561 --0.0002 0.56 0.56 0.00 
31 a 18 B 229 3 2.3 20.0 0.18 0.575 --0.0002 0.57 0.57 0.00 
46 19 B 36 2 7.0 60.0 0.774 0.0038 b 0.81 0.83 0.02 
33 22 B 80 4 5.0 40.0 0.54 0.572 0.0104 b 0.68 0.73 0.05 
49 28 B 69 2 10.0 15.0 1.020 --0.0052 0.97 0.94 -0.03 
50 29 B 30 2 15.0 60.0 0.443 0.0062 0.51 0.54 0.03 
12 38 B 82 2 10.0 15.0 0.850 0.0062 0.91 0.94 0.03 
52 39 B 72 2 15.0 60.0 0.738 --0.0022 0.71 0.70 -0.01 
Immune-compromised populations 
55 45 H1N1 51 2 15.0 30.0 0.229 0.0168 0.40 0.48 0.08 
55 46 H3N2 51 2 15.0 30.0 0.015 0.0124 0.14 0.20 0.06 
55 47 B 50 2 10.0 20.0 --0.058 0.0182 0.12 0.22 0.10 
0.78 0.79 
0.74 0.70 
0.21 0.77 0.76 
0.91 0.97 
0.04 0.80 0.85 
0.53 0.91 0.92 
0.59 0.89 0.93 
0.80 0.82 
0.44 0.81 0.83 
0.85 0.89 
0.14 0.72 0.76 
0.91 0.96 
0.93 0.93 
0.88 0.85 
0.61 0.62 
0.56 0.56 
0.19 0.57 0.57 
0.94 0.99 
0.70 0.72 0.81 
0.97 0.94 
0.44 0.54 
0.91 0.94 
0.73 0.70 
0.33 0.48 
0.12 0.20 
0.12 0.22 
Note that, for some stratification groups, the sizes may differ in Appendix 2 and in Tables 3-5, due 
original papers and those by us (see Appendix 1) 
aPossibly not randomized 
bSIope significantly different from 0 
to differences between inclusion criteria in the 
haemodialysis aS, the pattern appeared ifferent. The PR 
values at 10/~g HA were, for all three vaccine 
components, very low (12-40%), and showed an increase 
of 6 8% at a dose of l5 #g HA. 
Results yielded by probit analysis were similar to those 
of the linear model (last two columns of Table 4). Only 
one stratification group (SG 19) showed a major 
discrepancy between both methods (PR at 10/~g HA: 
81% by linear model, and 94% by probit), obviously 
related to the fact that, of all stratification groups with 
only two doses, SG 19 had the largest dose range 
(7-60/~g HA). 
Dose comparisons of response rates (Table 5). Thirty 
stratification groups could be analysed for response rates 
(RR) (Table 5). Both methods had insufficient model 
fitting in two cases (SG 25 and 33). In eight cases (SG 
30, 33, 5, 20, 32, 35, 45, 46), the doses did not include 
10 and 15 #g HA. The estimations for intercept, slope, 
and RR values at doses of 10 and 15 #g HA were very 
similar for both methods. With the linear model, nine 
stratification groups (30%) had a negative slope; of the 
remaining 21 positive slopes, four were significantly 
different from zero (SG 26, 6, 22, 47). Estimation of 
the RR at 10/~g HA, in non-immune-compromised 
populations, revealed a higher variability than for the 
protection rates, for all three virus subtypes/types 
(A-H3N2 34: 96%, median 85%; A-H1N1 39: 87%, 
median 76%; B 19: 98%, median 60%). Reasons for this 
variability may be related to the limitations of the 
response rate as a measure of seroresponse, and are 
addressed in the Discussion section of this review. 
Overall, the differences between RR values at doses of 
10 and 15/~g HA varied between -9  and 8% in 26 out 
of 27 stratification groups, with a median of 1%. Again, 
SG 20 had a higher difference between the two doses 
(16%). 
For patients on haemodialysis, the influenza B 
component (SG 47) showed the only huge increase, from 
an RR value of 20% at 10 #g HA to 41% at 15 #g HA. 
D ISCUSSION 
Until recently, dose requirements for influenza vaccines 
in various countries were different from each other, which 
indicated a lack of consensus on the 'lowest effective 
dose', despite the great number of studies done to 
investigate this question. This may be related to the 
biological or experimental difficulties in establishing such 
a dose. The lowest effective dose may vary for different 
virus strains, different epidemiological situations, or 
different arget groups, or may be dependent on the 
selected efficacy parameters to assess dose-effects. 
Dose-effects on the true efficacy parameters (influenza 
attack-rate, reduction in influenza-associated morbidity 
and mortality) can only be derived from field or challenge 
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Table 5 Estimation of response rates for doses of 10 and 15/~g HA 
Doses 
Ref. Stratification Model 
no. group Subtype Size No. Min. Max. fit 
Linear k*2 Z 2 analysis Probit analysis 
Dose (#9) Dose (I~9) 
Intercept Slope 10 15 Difference fit 10 15 
Non-immune-compromised populations 
44 4 H3N2 590 2 7.5 15.5 
29 11 H3N2 260 2 8.8 22.5 
48 24 H3N2 59 3 7.5 20.0 0.25 
25 25 H3N2 95 3 6.0 24.0 0.08 
51 30 H3N2 72 3 15.0 45.0 0.97 
51 33 H3N2 75 3 15.0 45.0 0.07 
12 36 H3N2 84 2 10.0 15.0 
53 a 44 H3N2 956 2 7.0 14.0 
44 5 HIN1 306 2 6.0 10.5 
29 9 H1N1 89 2 5.8 16.8 
29 10 H1N1 185 3 5.8 52.0 0.30 
47 20 H1N1 86 2 7.0 10.0 
48 23 H1N1 59 3 7.5 20,0 0.94 
26 26 H1N1 90 3 6,0 24.0 0.85 
51 31 H1N1 72 3 15.0 45.0 0.69 
51 34 H1N1 75 3 15.0 45.0 0.28 
12 37 HIN1 76 2 10.0 15.0 
54 a 43 HIN1 993 2 7.0 14.0 
44 6 B 590 2 19.5 33.5 
29 12 B 260 2 7.8 24.0 
46 19 B 47 2 7.0 60.0 
47 21 B 103 2 7.0 15.0 
33 22 B 96 4 5.0 40.0 0.29 
51 32 B 72 3 15.0 45.0 0.98 
51 35 B 75 3 15.0 45.0 0.48 
12 38 B 82 2 10.0 15.0 
52 39 B 129 2 15.0 60.0 
Immune-compromised populations 
55 45 H1N1 51 2 15.0 30.0 
55 46 H3N2 51 2 15.0 30.0 
55 47 B 51 2 10.0 20.0 
0.859 0.0018 0.88 0.89 0.01 0.88 0,89 
0.462 0.0070 0.53 0.57 0.04 0.54 0.58 
1.065 --0.0184 0.88 0.79 -0 .09  0.18 0.91 0.79 
0.874 0.0030 0.90 0.92 0.02 0.06 0.91 0.92 
0.291 0.0046 0.34 0.36 0,02 0.92 0.31 0.36 
0.539 0.0060 0,48 0.45 0.03 0.04 0.49 0.44 
0.867 0.0088 0.96 1.00 0.04 0.96 1.00 
0.864 0.0038 0.82 0.81 -0.01 0.82 0,81 
0.749 0,0048 0.70 0.68 -0 .02  0.70 0,69 
0.779 -0.0012 0.77 0.76 0.01 0.76 0.76 
0.424 0.0048 0.47 0.50 0.03 0.77 0.48 0.52 
0.554 0.0314 0.87 1.03 0.16 0.87 0,94 
0.926 0.0160 0.77 0.69 0.08 0.84 0.76 0.68 
0.628 0.0124 b 0.75 0.81 0,06 0.38 0.79 0.85 
0.345 0.0048 0.39 0.42 0.03 0.80 0.35 0.41 
0.472 0.0006 0.47 0.46 0.01 0.28 0.45 0,45 
0.807 0.0050 0.86 0.88 0.02 0.86 0.88 
0.770 0.0010 0.78 0.79 0,01 0.78 0.79 
0.640 0.0052 ~ 0.69 0.72 0.03 0.64 0.70 
0.330 0.0056 0.39 0.41 0.02 0.39 0.42 
0,659 0.0010 0.67 0.68 0.01 0.68 0.69 
0.456 0.0148 0.60 0.68 0.08 0.62 0.68 
0.532 0.0118 b 0,65 0.71 0,06 0.87 0,71 0.81 
0.172 0.0044 0.22 0.24 0,02 0.88 0.20 0.24 
0.194 -0 .0002 0.19 0.19 0.00 0.48 0.18 0.18 
0.990 -0 .0012 0.98 0.97 0.01 0.98 0.97 
0.498 0.0002 0,50 0.50 0.00 0.50 0.50 
0.591 0.0060 0.65 0.68 0.03 0.62 0.68 
0.422 0.0038 0.46 0.48 0.02 0.45 0.48 
-0 .215  0.0416 ~ 0.20 0.41 0.21 0.20 0.43 
See footnote to Table 4 
studies, the latter being feasible only in healthy adults 
for ethical reasons. Hence, for practical reasons, the 
choice for the recommended vaccine doses has mainly 
been based on serological studies where homologous 
antibody titres are used as surrogate markers of efficacy. 
The 20 studies selected for this review covered doses 
from 1.5 to 94/~g HA. We found a fair amount of 
variation in study designs, study samples, priming and 
vaccination history of the vaccinees, group sizes, vaccine 
types, virus strains, laboratory techniques and statistical 
procedures for data analysis. We applied strict post hoc 
criteria to each study to form 50 stratification groups of 
subjects already primed for the vaccine strains, collected 
the data on seroresponse measures as given in the studies, 
and performed calculations to detect dose-effects within 
the stratification groups and to estimate the seroresponse 
at doses of 10 and 15 #g HA. 
Quantitative seroresponse measures 
There was a significant dose response relationship 
based on post-GMT or mean fold increase (MFI) values 
in 11 out of 39 stratification groups. Of course, detection 
of such a relationship is dependent on group size and the 
range of doses included in the experiment, but even after 
exclusion of seven stratification groups with a very small 
dose range (~<7/~g HA), the number of significant 
results appears small (11/32, 34%), particularly since 
some stratification groups with a very large dose 
range are included. This finding could suggest hat a 
real relationship between antibody development after 
vaccination and vaccine dose does not exist at all, or is, 
at least, 'shallow '35. However, 34% with a significant 
result is far more than one would expect by chance in 
the absence of a real dose response relationship. More 
likely, in many studies other variables, insufficiently 
controlled, may have masked the dose-effect. The 
strongest determinant of postvaccination titre is the 
prevaccination (or baseline) titre 63"64 which was 
recognized and addressed in the majority of papers (Table 
1) but actually controlled only in two 52'53 where it was 
treated as a confounding factor in a statistical model. 
Response rate 
Another frequently used seroresponse measure in the 
papers reviewed was the RR used in 30 stratification 
groups (60%). Since RR is a dichotomous derivate of the 
MFI, it is also affected by the prevaccination antibody 
titre. In our opinion, this measure is mathematically 
inappropriate (even after statistically correcting for 
prevaccination titre), has no clear immunological or 
clinical implication, and should be avoided 14. Our 
theoretical considerations are confirmed by the large 
variability of the RR values when estimated for a dose 
of 10/~g HA (19 98%, Table 5). 
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Protection rate 
Clinically, the most meaningful seroresponse measure 
is the protection rate (PR). It is not strongly dependent 
on prevaccination titre as its calculation is based on 
subjects unprotected prior to vaccination (i.e. subjects 
with negative or low baseline). Therefore, this measure 
is also useful in studies which are insufficiently controlled 
for prevaccination titre. Indeed, the PR values estimated 
for a dose of 10/~g HA were much more consistent than 
the RR values. Virtually all stratification groups with 
influenza A had PR values equal to or higher than 75%. 
The papers consistently show that a dose of 10 #g HA 
of influenza A vaccine induces an antibody titre beyond 
the protection level in most primed and non-immune- 
compromised subjects. 
For influenza B, the variation in PR values was larger 
(51-97%), and fewer stratification groups exceeded a PR 
of 75% (3/9, 33%). It may be assumed that influenza B 
antigens are less immunogenic than influenza A. 
However, the observed lower PR values may be related 
to artefacts of the laboratory techniques, especially the 
haemagglutination nhibition test which tends to produce 
low titres with influenza B antigens 65. Some authors 
ignored this problem, others addressed it by treating the 
antigen with ether to enhance its avidity, and again 
others by using a lower protection threshold than for 
influenza A antigens (for instance, 20 instead of 40). All 
this may have contributed to the higher variability of PR 
values for influenza B; the reason for some less favourable 
findings could therefore be of a technical nature. 
Differences between PR and RR values for doses of 10 
and 15/zg HA 
Surprisingly, despite the limitations of the RR as a 
measure of seroresponse, and the PR in the case of 
influenza B, virtually no stratification groups for either 
RR or PR show a meaningful improvement when 
comparing their estimates for 10 and 15/~g HA. The 
stratification groups with a significantly positive slope 
show an increase of 2-6%,  and the increases of other 
stratification groups oscillate around zero in a range from 
-9  to 8% (except SG 47). This is in good agreement 
with our own dose response study in 544 young and 
elderly subjects, vaccinated with doses of 0, 10, 20 and 
60 ktg HA per strain 66. When treating the data by the 
same method as used in this review to interpolate PR 
values for 10 and 15/~g, we found the differences for three 
vaccine components and two age groups to vary between 
1 and 3% only. 
These results suggest that, at a dose level of 10 #g HA, 
the (sigmoid) dose-response curve has already passed 
the zone of its largest increase. An additional increase in 
the vaccine dose from 10 to 15 #g HA virtually does not 
improve the seroresponse as measured by protection or 
response rates. The expectation expressed in the 
European 'Harmonization ofRequirements For Influenza 
Vaccines '4 that a vaccine dose of 15/~g HA per strain 
should be clinically superior to a dose of 10/~g HA per 
strain is not justified in vaccinees who are primed and 
have no manifest immunological disorders. 
Immune-compromised subjects 
One paper 55 dealt with a group of 51 patients on 
chronic intermittent haemodialysis with a manifest 
Influenza vaccine dose: A.M. Palache et al. 
impairment of humoral immunity. There have been 
several unsuccessful attempts to overcome the low 
antibody production after influenza vaccination, for 
instance booster vaccinations ome weeks later 67 or 
simultaneous administration ofan immunomodulator 62. 
The results reported in Ref. 55 suggest that these patients 
might have benefited from a higher amount of antigen 
(for example, the simultaneous injection of two standard 
doses), and should stimulate more trials in this and 
similar immune-compromised groups. 
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APPENDIX  1 
In the following comments on the 20 papers reviewed, 
numbers of pages, figures or tables mentioned refer to 
the original papers, unless italicized. 
Nicholson et al. (Ref. 35) 
The authors describe a complex vaccination trial in 
nine groups of volunteers with different age distributions 
and in different locations, using four different vaccine 
preparations containing the A/USSR/77 (H 1N 1) strain, 
two different modes of vaccine administration, and many 
dosages. After 1 month, the young age groups received 
a booster injection with the same vaccine and dosage as 
the first vaccination. Of the 1335 subjects entering the 
study, the authors themselves exclude one group of 
unknown size because of assumed occurrence of natural 
influenza in this group during the trial. Prevaccination 
HI antibody titres (as cumulative percentages) are 
presented for 980 subjects (Table 1). On page 130 the 
authors state that they determined the HI antibody 
responses to vaccination for 972 subjects, but Tables 2-4 
present only 938 subjects. No comment is given on the 
missing subjects. From Tables 2 4, the distribution of 
subjects hown in Table A1  can be derived. 
Lavergne et aL (Ref. 44) 
Immunizations were performed in 667 healthy 
volunteers with two doses of a trivalent WV vaccine 
containing A/Texas/ I /77 (H3N2), A/USSR/92/77 
(H1N 1), and B/Hong Kong/2/73. Postvaccination sera 
of 77 subjects were not available. Serological data are 
presented for previously seronegative volunteers (Tables 
IVa-c) and all volunteers (Tables Va-c), stratified for 
three age groups (18 25, 26 50, 51-73 years of age). As 
the study population was regarded to be primed for 
influenza A (H3N2) and B, data of Tables Va and Vc 
were analysed in this review. For A/USSR/77, the data 
of age groups /> 26 years of age (primed), but not <26 
(unprimed, no booster vaccination performed) were used 
here. In Table Vc, the total postvaccination GMT for 
the lower dose group is not 73 but 75. As no serological 
data on prevaccination sera were presented, no PR values 
could be analysed. 
Table A1 
Influenza vaccine dose: A.M. Palache et al. 
Age 
groups Mode of Aqueous Aqueous Adsorbed 
(years) administration WV CTAB SU Triton SU Triton SU 
12-25 Subcutaneous 175 72 a 29 ~ 126 c 
Intradermal 44" 39 a 
>~26 Subcutaneous 128 46 a 61 94 c 
Intradermal 48 ~ 26 ~ 50" 
Totals 395 183 140 220 
Reasons for exclusion from this review: 
"The authors report that they had tested vaccine potency before 
delivering to and after returning from the study centres. The aqueous 
CTAB subunit vaccine lost all (low dosage) or much (high dosages) of 
its detectable HA contents, and data on antibody response were not 
reliable. For this review, those data are excluded 
~The 29 young subjects receiving aqueous Triton SU vaccine are 
excluded because only one dosage (9/~g HA) was given in this group 
COnly aqueous, but not adjuvant vaccine preparations (in this case 
Al(OH)3-adsorbed ), are accepted for this review. The remaining 364 
subjects form three different stratification groups 
~According to our selection criteria, only subjects with subcutaneous or 
intramuscular vaccine administration are included 
Brandriss et aL (Ref. 45) 
These authors undertook a vaccination trial in 137 
chronically ill, but not institutionalized, elderly, with 
monovalent or trivalent WV or SPL vaccines, in two 
dosages, and with booster vaccinations 3 weeks later. 
The authors did not present ables or figures showing 
the serological response on different doses, but only 
stated: ' . . .  when the subjects were combined according 
to dose (7/~g or 20/2g) . . .  the numbers were sufficient 
to suggest some significant differences in response. The 
postvaccination geometric mean titers to A/USSR/77 
were higher after the 20 #g dose than after the 7 #g dose 
(I :144 versus 1:88.2, p<0.01) and were also higher to 
A/Texas/77 after 20 #g (1:87 versus 1:59.7, p<0.05). 
There were no significant differences between the 7-/~g 
and the 20-/~g preparations in the percentage of 
responders or the percentages of subjects with postvaccine 
HAI titers equal to or greater than 1:40.' 
Quinnan et aL (Ref. 29) 
A complex study is described which includes 517 
subjects, with placebo (91 subjects) or monovalent and 
trivalent vaccine preparations from four manufacturers 
(WV and SPL), and booster injections for A/USSR/77 
(H1N1) with the same vaccine preparation and dose as 
the first vaccinationl Numbers given in thetables donor  
always correlate with numbers in the text. There were 
no titre rises in the placebo subjects, suggesting absence 
of natural influenza during the performance of the trial. 
Data for the different vaccine preparations were pooled 
by the authors. Instead of the numerical vaccine dosages 
(7, 20, 60/~g HA), the real mean dosages as given in 
Tables 1 and 2 are used in this review. Table 1 
(A/USSR/77) includes two age groups (16-25 years of 
age, unprimed, n = 132 subjects, and /> 26 years of age, 
primed, n= 185 subjects). Stratification has been done, 
by the authors, for previous vaccination with A/NJ/76 
(Table 3), but the numbers cannot be correlated to those 
in Table 1. Therefore, this stratification is not included 
here. The authors found no major differences between 
subjects previously vaccinated and those not vaccinated 
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Table 
Groups by authors (according to Table 4) 
Vaccine type 
Strain Age group and dose Group 
Stratification groups for review 
Comments 
A/USSR Young adults 7 ,ug WV 17 
A/USSR Young adults ? ,ug SPL 24 
A/USSR Young adults 20 #g WV 18 
A/USSR Young adults 20/~g SPL 21 
A/USSR Older adults 98 
A/Tex Young adults 7 ,ug WV 25 
A/Tex Young adults 7/~g SPL 28 
A/Tex Young adults 20 rug WV 23 
A/Tex Young adults 20 rug SPL 26 
B/HK Young adults 7/~g WV 25 
B/HK Young adults 7 ,ug SPL 28 
B/HK Young adults 20 ,ug WV 23 
B/HK Young adults 20 ,ug SPL 26 
A/Tex Older adults 7 ,ug WV 19 
A/Tex Older adults 7/~g SPL 20 
A/Tex Older adults 20 ,ug WV 40 
A/Tex Older adults 20/~g SPL 37 
B/HK Older adults 7 #g WV 19 
B/HK Older adults 7/~g SPL 20 
B/HK Older adults 20 iLg WV 40 
B/HK Older adults 20 ,ug SPL 37 
13-1 
13-2 
14-1 
14-2 
15-1 
15-2 
A/USSR unprimed 7 l~g (n=41) 
Pooled with 13-1 
A/USSR unprimed 20,ug (n-39) 
Pooled with 13-2 
Excluded because authors pooled 
20 and 60 ,ug HA doses 
A/Tex 7/~g (n-92)  
Pooled with 14-1 
A/Tex 20 ,ug (n - 126) 
Pooled with 14-2 
B/HK 7pg (n=92) 
Pooled with 15-1 
B /HK20#g (n 126) 
Pooled with 15-2 
Pooled with 14-1 
Pooled with 14-1 
Pooled with 14-2 
Pooled with 14-2 
Pooled with 15-1 
Pooled with 15-1 
Pooled with 15-2 
Pooled with 15-2 
by A/NJ/76. For the unprimed age group, values after 
second vaccination are included. There are different total 
numbers of volunteers after the first and second 
vaccinations, but the percentages of protected subjects 
and the GMT values before vaccination are not given 
for the booster groups. For calculations, the respective 
values were adapted from the groups after first 
vaccination. Table 2 (A/Texas/77 (H3N2) and B/Hong 
Kong/72) presents the cumulated ata of all ages, for 
260 subjects. 
Cate et al. (Ref. 30) 
A study design was used similar to that described in 
Ref. 29, with monovalent and trivalent vaccines from four 
manufacturers (WV and SPL), two (7, 20 #g HA) or three 
doses (7, 20, 60#g HA), and booster injections for 
A/USSR/77 (H1N1) after 1 month, in two groups of 
volunteers (age range 20 33 years of age, n= 154, and 
45 88 years of age, n= 138). On page 738, the age range 
of the first group is wrongly given as 20 23. No 
information is given about the serology of the placebo 
groups. Unfortunately, data for 20 and 60 #g HA in the 
older adult age group vaccinated with A/USSR/77 
(H1N1), were pooled by the authors as they found 'no 
major differences' between those dosages. These 
stratification groups had to be excluded as we were 
especially interested in those differences. Table 3 presents, 
according to priming periods, the immune response to 
A/USSR/77 (H1N1) only for 20 25-year-old and 
55 88-year-old subjects. Table 4 gives the protection and 
response rates, but not the pre- and post-GMT-values, 
for all young and older subjects for all three antigens. 
This latter table was used for our review. Response rates, 
however, could not be used, as they were based on an 
unknown number of subjects with a prevaccination titre 
<~20. In total, 80 subjects could be included for the 
A/USSR/77 strain, and 218 subjects for A/Texas/77 and 
B/Hong Kong/72, respectively. We pooled the data for 
WV and SPL preparations. For A/Texas and B/Hong 
Kong, data for both age groups were pooled. 
Table A2  shows the comparison groups presented by 
the authors, and the pooling which has been made for 
this review. 
Wright et al. (Ref. 31) 
The authors use a study design similar to that in Ref. 
29 with monovalent and trivalent SV and SPL vaccine 
preparations from four manufacturers, three dosages (2.3, 
7, 20 #g HA), and booster injections for A/USSR/77 
(H1N1). There were 358 children and 676 young adults 
(healthy and chronically ill, total 1034, of whom 235 
received placebo). No information isgiven about random 
allocation of vaccine doses to subjects. Whether 
allocation was really done is doubtful, at least for the 
lowest dose, as the authors stated: 'It may also reflect 
the fact that the lowest vaccine dose (pediatric), which 
contained +2.3 pg of antigen, was selectively given to 
younger children . . . .  '. Table 6 presents the antibody 
response to A/USSR/77 (H1N1) of initially seronegative 
subjects. For our review, data of different age classes 
(3 6, 7 12 and 13 25 years of age) and vaccine 
preparations were pooled to form a group of unprimed 
subjects. Of these, 355 received a booster dose; those 
data were included here. Table 7 presents the antibody 
responses to A/Texas/77 and B/Hong Kong/72 of 
initially seronegative subjects for the age classes 3 6, 
7 12, and 13 25 years. The first age class was supposed 
to be unprimed, and its data were not included, as booster 
vaccination had not been done for those vaccine strains. 
The other two age classes, although seronegative prior 
to vaccination, were supposed to be primed, and their 
data were pooled and included here. 
Gross et aL (Ref. 46) 
This study was conducted in patients with cystic 
fibrosis (children, young adults), in part from St. 
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Vincent's Hospital, as was the case in Ref. 28. It can be 
assumed that some in this study group also participated 
in that former study, but information about previous 
vaccination is not given. Two doses (7, 60/~g HA) of 
B/Singapore/79 are compared, given in a trivalent 
vaccine containing also 7 ktg HA/Bangkok/1/79 (H3N2) 
and 7#g A/Brazil/78 (H1N1). Dose groups were 
subdivided into subjects with negative and positive 
prevaccination titres for B/Singapore/79. The authors 
assume that previously seronegative subjects were 
unprimed for influenza B, which has been confirmed by 
a neutralization test. After 1 month most subjects in both 
dosage groups received a trivalent booster vaccine 
containing 7 #g HA of each strain. As this latter booster 
vaccination did not contain different dosages, only the 
data of the first vaccination in primed subjects were 
included in this review. 
Moffat et aL (Refo 47) 
A trivalent WV vaccine was used to immunize 108 
adult volunteers of whom 105 completed the study. 
The vaccine contained either 7/~g HA of each 
strain (A/Texas/1/77 (H3N2), A/Brazil/11/78 (H1N1), 
B/Singapore/222/79), or 7#g HA A/Texas/ I /77 
(H3N2), 10/~g HA A/Brazi l / l l /78 (H1N1)and 15~tg 
HA B/Singapore/222/79. Thus, dose comparisons could 
be made for A/Brazil (7 versus 10/~g HA) and 
B/Singapore (7 versus 15/~g HA). Table 2 addresses the 
different H1Nl-priming state for subjects born before 
and after 1956, for A/Brazil; no significant difference was 
found. Tables 1 and 3 present data on A/Brazil and 
A/Singapore, respectively, stratified for all participants, 
and for those with prevaccination titres <40; the latter 
stratification was chosen here. For the influenza B strain, 
the authors did not choose a protection threshold. 
Goodeve et aL (Ref. 33) 
After determining the serostatus of 119 healthy 
students, Goodeve and colleagues tested four dosages of 
a B/Hongkong/73 SU (CTAB) vaccine and placebo. No 
response occurred in the placebo group (n = 23), thus no 
natural influenza was present After 4 weeks, volunteers 
were challenged with attenuated live virus. Tables 2 and 
3 give data on the seroresponse to vaccination. In our 
review, the protection rates were calculated from Table 
2 (subjects with titres >40, i.e. ~>60, were supposed to 
be protected), and GMT values from Table 3. 
Rudenko et aL (Ref. 48) 
Eighty healthy volunteers were vaccinated with a 
trivalent SU vaccine containing A/Texas/ I /77 (H3N2), 
A/Khabarovsk/74/77 (H1N1) and B/Hong Kong/8/73, 
on three dose levels and placebo-controlled, and with 
booster vaccination 1 month later. Serological data are 
given in Tables 1 and 2. The authors used the term 
'seroconversion' rate without definition; we supposed it 
to be the response rate. We did not include data on 
influenza B, as titrations were done with a strain different 
from the vaccine strain (B/Leningrad/369/75). The 
vaccine series '01 i.m.' and '07 s.c.' were pooled by us, 
as they both contained 15/~g HA of each strain. 
Influenza vaccine dose: A.M. Palache et al. 
Jennings et al. (Ref. 25) 
The authors evaluated three doses of a trivalent 
SU vaccine containing A/Bangkok/ I /79 (H3N2), 
A/Brazil/11/78 (H1NI) and B/Lyon/1847/79, in young 
adults in a placebo-controlled study. The number of the 
volunteers entering the study is not given in the text of 
the paper; Table 1 reports on 132 subjects, Table 2 on 
127 subjects including those receiving placebo. During 
the trial, there were natural influenza B infections among 
the participants (five out of 32 subjects receiving placebo); 
the data on the influenza B vaccine component were, 
therefore, not included here. Pre- and postvaccination 
antibody concentrations, presented as mean areas of 
haemolysis (in mm 2) were adapted from Table 2. In the 
text, the differences in postvaccination mean areas 
between the doses were described as not significant for 
the H3N2 vaccine strain. About the H1N1 vaccine strain, 
the text said: 'High postimmunization mean SRH 
antibody levels were also observed against A/Brazil, 
irrespectively of vaccine dosage administered'. This was 
interpreted by us as absence of significant differences 
between dosages for that strain as well. RR values were 
adapted from Table 1. Protection rates could not be 
calculated as the number of subjects protected before 
vaccination was not given. 
Clarke et al. (Ref. 49) 
Using the vaccine composition recommended for the 
season 1984/1985, two dosages of trivalent SPL vaccine 
were administered: A/Philippines/82 (H3N2) 10 versus 
10, A/Chile/83 (H1N1) 10 versus 15, B/USSR/83 10 
versus 15/~g HA. Thus, since for A/Philippines/82 
(H3N2) no dose-response data are available, this strain 
has not been included in our review. Seroconversion is 
defined dependent on serostatus (seronegative subjects 
reaching a titre >40 after vaccination, seropositive 
subjects howing a fourfold increase), thus a combination 
of response and protection rate (Table 1). Those data 
are not included in our review. Protection rates and GMT 
values are derived from Table 3. 
Arden et al. (Ref. 50) 
Elderly, chronically ill subjects were vaccinated with 
trivalent SPL vaccine (15/~g HA each of A/Phi l ippines/82 
(H3N2), A/Chile/83 (H 1N1) and B/USSR/83), and with 
either placebo or 45/~g HA B/USSR/83, thus a 
comparison between 15 and 60 #g HA B/USSR/83 was 
made. GMT values are described in the text. The authors 
tested the difference between the MFI values for the two 
dose groups and found p = 0.956 by Wilcoxon's rank sum 
test. This was regarded as not significant by the authors, 
and in this review. Table 1 presents the protection rates 
for subjects unprotected before vaccination (<40). The 
authors used a one-tailed Fisher's exact est and regarded 
the difference between the protection rates as significant 
(p<0.05). In a two-tailed fashion this test would give 
p = 0.0816, thus a non-significant difference for ~ = 0.05. 
Gross et aL (Ref. 51) 
A comparison is made between three dosages of two 
trivalent vaccine preparations (split, WV), thus 18 
groups, in healthy, ambulatory elderly (health state well 
defined, mean ages given as 71 74, no age range 
reported). Of the subjects, 56 76% had been vaccinated 
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previously. Correction for prevaccination state is not 
discussed. The total number of volunteers i given as 148 
in the text, but as 147 in Table 1. The numbers for 
split/Chile groups and WV/Chile groups are obviously 
confused in Table 1. The protection rates cannot be 
calculated because prevaccination data are not given. 
The authors report a significant difference in post- 
vaccination GMT between groups split/Chile/15 #g and 
split/Chile/45 #g, but when calculating MFI values, this 
difference is smaller because the prevaccination GMT 
values differ in these groups. Whether actual MFI values 
differ significantly cannot be decided here. The 15 #g HA 
dose groups are compared with a group of children with 
cystic fibrosis and young adults (n=21); these data are 
not included here. 
Beyer et aL (Ref. 12) 
Data are presented on healthy young students 
vaccinated with trivalent SPL vaccine, either 10 or 15 #g 
HA of each strain. The volumes of both doses differed 
per syringe (0.50 versus 0.75 ml), thus it can be assumed 
that the administration of vaccines was single-blinded 
but not double-blinded, as is stated in the text. Subjects 
were pretested for low prevaccination antibody titres. 
For calculations, subjects with high (protective) pre- 
vaccination antibody titres (influenza A > 100, influenza 
B, ether-treated > 200) were excluded. Absolute pre- and 
post-GMT values were recalculated from logarithm 
values. Table 4 also presents heterologous response to 
four other strains, and, as parameters, MFI and 
protection rates of responders only. These data were not 
included in this review. 
Peters et aL (Ref. 52) 
The authors describe a trial in elderly, some chronically 
ill, non-institutionalized subjects receiving trivalent 
vaccine (no information about vaccine type) each 
containing 15 #g HA of A/Philippines/82 (H3N2) and 
A/Chile/83 (HINI),  and either 15#g B/USSR/83 
(group I) or 60 #g B/USSR/83 (group III) into the right 
upper arm and, into the left upper arm, either placebo 
(group I and III) or 45 #g HA B/USSR/83 (group II). 
Numbers of subjects for pre- and first postvaccination 
sera: Group I, 42, group II, 44, group III, 45 -2=43.  
The data of groups II and III, receiving a total amount 
of 60#g HA, have been pooled here. A second 
postvaccination sample (after 5 months) was drawn, but 
data are not presented here. Also, data about 
heterologous response were not included (they showed 
a difference between doses). The authors analysed 
the data by a regression model including age (not 
dependent), prevaccination state (dependent), and 
previous vaccinations (dependent). 
Sullivan et aL (Ref. 53) 
Healthy university personnel and students received a 
trivalent Triton-split vaccine containing A/Philippines/82 
(H3N2), A/Chile/83 (H1N1) and B/USSR/83 with 7.5, 
7.5, 7.5, or 15, 15, 15 or 30, 30, 30, or 15, 15, 45 #g HA. 
Thc authors combine the data of A/Philippines/82 
(H3N2) and A/Chile/83 (H1N1) of the second and the 
fourth group. The authors looked at the data on response 
and protection rates (~>32), but, unfortunately, did not 
present these data as they did not find significant 
differences between dose groups for any strain. 
Subbotina et al. (ReL 54) 
A mass vaccination trial is described in 2062 children 
and young adults (9 22 years of age) with a bivalent WV 
vaccine containing A/Kiev/59/79 (HINI)  and A/ 
Leningrad/385/80 (H3N2). The vaccine doses were 
reported as 6 8 and 12 16#g HA; we used 7 and 14#g 
HA, respectively, for calculations. Whether a random 
allocation had been applied could be doubted considering 
the following statement: 'Vaccinations were conducted 
step by step starting with the oldest group to 
the youngest, first with a 6 8 #g HA dosage and then 
with the 12 16 #g HA dose'. Table 2 presents erological 
data for different age groups (pooled by us). The term 
'seroconversion' is used but not defined by the authors: 
we supposed it to be an at least fourfold titre increase in 
subjects eronegative before vaccination. 
Rautenberg et aL (Ref. 55) 
Fifty-one patients on chronic intermittent haemodialysis 
were immunized with either a conventional dose (plus 
booster dose 5 weeks later), or a double dose ofa trivalent 
SPL vaccine containing A/Singapore/6/86 (HINI),  
A/Leningrad/360/86 (H3N2) and B/Ann Arbor/I/86. 
They used an indirect immunofluorescent test for IgA 
and IgG antibodies. Data were presented in Figures 1 
and 2, and read, by us, for weeks 0 and 5 after (first) 
vaccination although sometimes peaks were reached at 
week 6. The presentation of the GMT values (as negative 
potency to the base 2) was changed by us (as reciprocal). 
Guarnaccia et al (Ref. 56) 
This study evaluated the practice of clinicians who 
diluted vaccine when immunizing subjects with allergy 
to egg proteins. In 29 healthy subjects (intake: 30), 
commercially available trivalent vaccine of unknown type 
was tested as original volume (0.5 ml), and as 1:5 and 
1:10 dilutions. No information about contents in #g HA 
was given. Assuming 15 #g HA dose for the undiluted 
vaccine, as used in the United States at the time of 
performance of this study, the dosage groups would be 
1.5, 3 and 15 #g HA. Little information on study design 
and no data about response or protection rates are 
provided. Pre- and 28-day-post-GMT-values are derived 
from Figures 1 3 according to GMT = exp(L*0.07 + 1.6), 
where L is the length of bar in mm. According to 
ANOVA done by authors, post-GMT of high and lower 
dosages differ significantly for the influenza A strains, 
but not for influenza B. However, pre- and post- 
vaccination titres together formed the dependent variable 
of the analysis, while the dosage was an independent 
variable. Whether the differences between the MFI values 
for influenza A strains were also significant cannot be 
judged here. 
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Serological data from 20 dose-response tudies 
Influenza vaccine dose: A.M. Palache et  al .  
Strat i f icat ion Dose Pre Post Pre Post N2 N RR 
Ref. g roup  (/~g HA) N1 GMT GMT MFI prot prot  PR Resp 
35 1 5.0 21 5 58 1.06 0 14 0.67 - - 
35 1 9.0 21 5 63 1.10 0 14 0.67 - - - 
35 1 16.0 51 5 111 1.35 2 48 0.94 - - - 
35 1 32.0 17 5 153 1.49 0 13 0.76 - - 
35 1 46.0 53 5 201 1.60 1 51 0.96 - 
35 1 94.0 12 5 187 1.57 0 12 1~00 
35 2 5.0 22 10 276 1.44 4 19 0.83 - - 
35 2 9.0 15 16 250 1.19 4 14 0.91 - 
35 2 16.0 26 13 562 1.64 5 26 1.00 - - 
35 2 32.0 33 10 275 1.44 5 31 0.93 - - 
35 2 46.0 20 13 465 1.55 4 19 0.94 - 
35 2 94.0 12 12 397 1.52 3 11 0.89 - 
35 3 5.0 16 13 346 1.43 5 14 0.82 - 
35 3 18.0 29 5 343 1.84 3 27 0.92 - - 
35 3 66.0 16 11 495 1.65 3 16 1.00 
44 4 7.5 189 318 - 189 165 0.87 
44 4 15.5 401 - 325 - - - 401 356 0.89 
44 5 6.0 43 126 - - 43 31 0.72 
44 5 10.5 263 147 - - 263 184 0.70 
44 6 19.5 189 - 73 - - 189 140 0.74 
44 6 33.5 401 171 - - 401 326 0.81 
45 7 7.0 ng 88 . . . .  
45 7 20.0 ng 144 - - - 
45 8 7.0 ng - 60 . . . .  
45 8 20.0 ng - 87 - 
29 9 7.0 48 12 71 0.77 9 39 0.77 48 37 0.77 
29 9 20.0 41 14 96 0.84 12 36 0.83 41 31 0.76 
29 10 7.0 81 48 129 0.43 49 75 0.81 81 34 0.42 
29 10 20.0 88 46 170 0.57 53 81 0.80 88 48 0.55 
29 10 60.0 16 22 89 0.61 4 15 0.92 16 10 0.62 
29 11 7.0 26 17 63 0.57 35 106 0.78 26 66 0.52 
29 11 20.0 34 18 65 0.56 40 115 0.80 34 83 0.62 
29 12 7.0 26 20 50 0.40 40 92 0.60 26 47 0.37 
29 12 20.0 34 21 75 0.55 51 103 0.63 34 62 0.46 
30 13 7.0 41 - - 2 33 0.79 - - - 
30 13 20.0 39 - - 2 36 0.92 
30 14 7.0 92 - - 32 78 0.77 - - 
30 14 20.0 126 - 45 100 0.68 - - 
30 15 7.0 92 - 24 62 0.56 - 
30 15 20.0 126 - 45 90 0.56 - - 
31 a 16 2.3 42 5 39 0.89 0 28 0.67 - 
31 a 16 7.0 161 5 39 0.89 0 106 0.66 - 
31 a 16 20.0 152 5 56 1.05 0 121 0.80 
31 a 17 2.3 4 5 80 1.20 0 4 1.00 - 
31" 17 7.0 49 5 55 1.04 0 36 0.73 - 
31 a 17 20.0 58 5 80 1.20 0 45 0.78 
31 a 18 2.3 9 5 86 1.24 0 7 0.78 - 
31 a 18 7.0 109 5 36 0.86 0 60 0.55 - - 
31 a 18 20.0 111 5 44 0.95 0 64 0.58 - - - 
46 19 7.0 18 15 84 0.75 3 15 0.80 18 12 0.67 
46 19 60.0 29 20 170 0.93 8 29 1.00 29 21 0.72 
47 20 7.0 40 8 125 1.19 0 34 0.85 40 31 0.78 
47 20 10.0 46 9 172 1.28 0 42 0.91 46 40 0.87 
47 21 7.0 50 6 20 0.52 - 50 28 0.56 
47 21 15.0 53 5 31 0.79 53 36 0.68 
33 22 5.0 25 17 87 0.71 8 18 0.59 25 13 0.52 
33 22 10.0 24 17 138 0.91 4 17 0.65 24 16 0.67 
33 22 20.0 24 10 153 1.18 2 21 0.86 24 21 0.88 
33 22 40.0 23 9 322 1.55 2 22 0.95 23 22 0.96 
48 23 7.5 10 6 42 0.85 10 8 0.80 
48 23 15.0 29 6 52 0.94 29 20 0.69 
48 23 20.0 20 6 120 1.30 20 12 0.60 
48 24 7.5 10 9 158 1.24 - - 10 10 1.00 
48 24 15.0 29 6 95 1.20 29 21 0.72 
48 24 20.0 20 6 91 1.18 - 20 15 0.75 
25 25 6.0 32 15 103 6.87 - - 32 30 0.94 
25 25 12.0 31 14 88 6.29 31 26 0.84 
25 25 24.0 32 12 86 7.17 - - 32 31 0.97 
25 26 6.0 32 30 104 3.47 - 31 22 0.71 
25 26 12.0 31 29 125 4.31 - - 30 23 0.77 
25 26 24.0 32 22 123 5.59 - 29 27 0.93 
49 27 10.0 47 20 900 1.65 18 45 0.93 - - 
49 27 15.0 49 20 930 1.67 19 47 0.93 
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Stratification Dose Pre Post Pre Post N2 N RR 
Ref. group (#g HA) N1 GMT GMT MFI prot prot PR Resp 
49 28 10.0 47 10 240 1.38 14 
49 28 15.0 49 10 200 1.30 13 
50 29 15.0 25 25 66 0.42 12 
50 29 60.0 25 19 77 0.61 8 
51 30 15.0 25 19 43 0.35 
51 30 30.0 23 14 44 0.50 
51 30 45.0 24 22 70 0.50 
51 31 15.0 25 13 38 0.47 
51 31 30.0 23 11 50 0.66 
51 31 45.0 24 18 76 0.63 
51 32 15.0 25 18 43 0.38 
51 32 30.0 23 20 50 0.40 
51 32 45.0 24 19 54 0.45 
51 33 15.0 24 13 28 0.33 
51 33 30.0 26 11 32 0.46 
51 33 45.0 25 22 27 0.09 
51 34 15.0 24 21 62 0.47 
51 34 30.0 26 19 60 0.50 
51 34 45.0 25 24 58 0.38 
51 35 15.0 24 16 28 0.24 
51 35 30.0 26 18 31 0.24 
51 35 45.0 25 14 22 0.20 
12 36 10.0 45 10 318 2.10 0 
12 36 15.0 39 11 622 2.15 0 
12 37 10.0 42 8 490 1.78 0 
12 37 15.0 34 9 407 1.64 0 
12 38 10.0 46 11 202 2.02 0 
12 38 15.0 36 10 741 1.88 0 
52 39 15.0 42 18 78 0.64 15 
52 39 60.0 87 27 94 0.54 42 
53 40 7.5 35 5 19 0.58 
53 40 15.0 70 4 18 0.65 
53 40 30.0 35 5 27 0.73 
53 41 7.5 35 8 53 0.82 
53 41 15.0 70 8 70 0.94 
53 41 30.0 35 11 105 0.98 
53 42 7.5 35 6 36 0.78 
53 42 15.0 35 6 30 0.70 
53 42 30.0 35 6 37 0.79 
53 42 45.0 35 6 45 0.88 
54 a 43 7.0 603 9 104 1.06 
54 a 43 14.0 534 10 157 1.21 
54 a 44 7.0 603 9 108 1.09 
54 ~ 44 14.0 534 9 128 1.13 
55 45 15.0 25 549 1783 0.51 0 
55 45 30.0 26 446 2702 0.78 0 
55 46 15.0 25 64 362 0.75 0 
55 46 30.0 26 97 832 0.93 0 
55 47 10.0 25 294 676 0.36 1 
55 47 20.0 26 194 832 0.63 0 
56 48 1.5 10 7 32 0.66 
56 48 3.0 10 11 73 0.82 
56 48 15.0 9 14 153 1.04 
56 49 1.5 10 22 47 0.33 
56 49 3.0 10 19 104 0.74 
56 49 15.0 9 26 176 0.83 
56 50 1.5 10 8 17 0.33 
56 50 3.0 10 9 23 0.41 
56 50 15,0 9 9 38 0.63 
46 0.97 
47 0.94 
19 0.54 
22 0.82 
41 
38 
37 
29 
42 
34 
34 
69 
0.91 
0.97 
0.88 
0.85 
0.91 
0.94 
0.70 
0.60 
12 0.48 
19 0.73 
5 0.20 
10 0.38 
4 0.13 
8 0.31 
25 9 0.36 
23 10 0.43 
24 12 0.50 
25 10 0.40 
23 12 0.52 
24 13 0.54 
25 6 0.24 
23 7 0.30 
24 9 0.38 
24 9 0.38 
26 13 0.50 
25 5 0.20 
24 10 0,42 
26 14 0.54 
25 10 0.40 
24 4 0.17 
26 6 0.23 
25 4 0.16 
45 43 0.96 
39 39 1.00 
42 36 0.86 
34 30 0.88 
46 45 0.98 
36 35 0.97 
42 21 0.50 
87 44 0,51 
525 408 0.78 
468 367 0.78 
509 426 0.84 
447 362 0.81 
25 17 0.68 
26 20 0.77 
25 12 0.48 
26 14 0.54 
25 5 0.20 
26 16 0.62 
N1, size of dose group for calculation of GMT and PR; Pre GMT/Post GMT, absolute pre-/postvaccination geometric mean titre; MFI, Iogarithmated 
meanfold increase: log(Post GMT/Pre GMT); Pre prot/Post prot, number of subjects protected before/after vaccination; PR, protection rate: (Post 
prot-Pre prot)/(Nl-pre prot); N2, size of dose group for calculation of RR; Nresp, number of responders (subjects with >~4-fold titre rise); RR, 
response rate (Nresp/N2); -, missing value; ng, not given 
aPossibly not randomized 
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